- Reuters•2 hours ago
GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market. Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax. The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to revitalise a drug portfolio hit by falling sales of best-selling inhaled lung treatment Advair.
- Reuters•3 hours ago
GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market. Shingrix is viewed by analysts as among ...
- Bloomberg•3 hours ago
GlaxoSmithKline Plc said it sought regulatory approval in the U.S. for its experimental shingles vaccine which, if successful, could generate more than $700 million in annual sales for the British drugmaker ...
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||41.14 x 3900|
|Ask||41.18 x 5200|
|Day's Range||40.96 - 41.25|
|52wk Range||37.82 - 45.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||2,570.62|
|Avg Vol (3m)||2,682,029|
|Dividend & Yield||1.87 (4.54%)|